FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058769962> ?p ?o ?g. }

• W2058769962 endingPage "493" @default.
• W2058769962 startingPage "485" @default.
• W2058769962 abstract "Bevacizumab or temsirolimus regimens have clinical activity in the first-line treatment of advanced renal cell carcinoma (RCC). This phase I/II trial was conducted to determine the safety of combining both agents and its efficacy in RCC patients who progressed on at least one prior anti-VEGF receptor tyrosine kinase inhibitor (RTKI) agent.In the phase I portion, eligible patients were treated with temsirolimus (25 mg IV weekly) and escalating doses of IV bevacizumab (level 1 = 5 mg/kg; level 2 = 10 mg/kg) every other week. The primary endpoint for the phase II portion (RTKI resistant patients) was the 6-month progression-free rate. Secondary endpoints were response rate, toxicity evaluation, and PFS and OS.Maximum tolerated dose was not reached at the maximum dose administered in 12 phase I patients. Forty evaluable patients were treated with the phase II recommended dose (temsirolimus 25 mg IV weekly and bevacizumab 10 mg/kg IV every 2 weeks). The 6-month progression-free rate was 40 % (16/40 pts). Median PFS was 5.9 (4-7.8) months, and median OS was 20.6 (11.5-23.7) months. Partial response, stable disease, and progressive disease were seen in 23, 63, and 14 % of patients, respectively. Most common grade 3-4 AEs included fatigue (17.8 %), hypertriglyceridemia (11.1 %), stomatitis (8.9 %), proteinuria (8.9 %), abdominal pain (6.7 %), and anemia (6.7 %). Baseline levels of serum sFLT-1 and VEGF-A were inversely correlated with PFS and OS, respectively.Temsirolimus and bevacizumab is a feasible combination in patients with advanced RCC previously exposed to oral anti-VEGF agents. The safety and efficacy results warrant further confirmatory studies in this patient population." @default.
• W2058769962 created "2016-06-24" @default.
• W2058769962 creator A5012465182 @default.
• W2058769962 creator A5016095265 @default.
• W2058769962 creator A5017792432 @default.
• W2058769962 creator A5022511085 @default.
• W2058769962 creator A5027306320 @default.
• W2058769962 creator A5029941846 @default.
• W2058769962 creator A5030084075 @default.
• W2058769962 creator A5032135930 @default.
• W2058769962 creator A5034354367 @default.
• W2058769962 creator A5046981381 @default.
• W2058769962 date "2015-01-03" @default.
• W2058769962 modified "2023-10-07" @default.
• W2058769962 title "Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study" @default.
• W2058769962 cites W2023952988 @default.
• W2058769962 cites W2024586523 @default.
• W2058769962 cites W2029409133 @default.
• W2058769962 cites W2067874044 @default.
• W2058769962 cites W2068466600 @default.
• W2058769962 cites W2082830752 @default.
• W2058769962 cites W2087073539 @default.
• W2058769962 cites W2094556354 @default.
• W2058769962 cites W2095370944 @default.
• W2058769962 cites W2096093767 @default.
• W2058769962 cites W2099752220 @default.
• W2058769962 cites W2106858635 @default.
• W2058769962 cites W2115005218 @default.
• W2058769962 cites W2116949558 @default.
• W2058769962 cites W2117924296 @default.
• W2058769962 cites W2120129511 @default.
• W2058769962 cites W2130826590 @default.
• W2058769962 cites W2135647551 @default.
• W2058769962 cites W2138129102 @default.
• W2058769962 cites W2139248078 @default.
• W2058769962 cites W2143180984 @default.
• W2058769962 cites W2146711059 @default.
• W2058769962 cites W2149456801 @default.
• W2058769962 cites W2153867442 @default.
• W2058769962 cites W2158303916 @default.
• W2058769962 cites W2160476851 @default.
• W2058769962 cites W2160724351 @default.
• W2058769962 cites W2160834915 @default.
• W2058769962 cites W2162424705 @default.
• W2058769962 cites W2560367415 @default.
• W2058769962 cites W4243256438 @default.
• W2058769962 doi "https://doi.org/10.1007/s00280-014-2668-5" @default.
• W2058769962 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4348698" @default.
• W2058769962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25556030" @default.
• W2058769962 hasPublicationYear "2015" @default.
• W2058769962 type Work @default.
• W2058769962 sameAs 2058769962 @default.
• W2058769962 citedByCount "14" @default.
• W2058769962 countsByYear W20587699622015 @default.
• W2058769962 countsByYear W20587699622016 @default.
• W2058769962 countsByYear W20587699622017 @default.
• W2058769962 countsByYear W20587699622018 @default.
• W2058769962 countsByYear W20587699622019 @default.
• W2058769962 countsByYear W20587699622020 @default.
• W2058769962 crossrefType "journal-article" @default.
• W2058769962 hasAuthorship W2058769962A5012465182 @default.
• W2058769962 hasAuthorship W2058769962A5016095265 @default.
• W2058769962 hasAuthorship W2058769962A5017792432 @default.
• W2058769962 hasAuthorship W2058769962A5022511085 @default.
• W2058769962 hasAuthorship W2058769962A5027306320 @default.
• W2058769962 hasAuthorship W2058769962A5029941846 @default.
• W2058769962 hasAuthorship W2058769962A5030084075 @default.
• W2058769962 hasAuthorship W2058769962A5032135930 @default.
• W2058769962 hasAuthorship W2058769962A5034354367 @default.
• W2058769962 hasAuthorship W2058769962A5046981381 @default.
• W2058769962 hasBestOaLocation W20587699622 @default.
• W2058769962 hasConcept C126322002 @default.
• W2058769962 hasConcept C126894567 @default.
• W2058769962 hasConcept C141071460 @default.
• W2058769962 hasConcept C143998085 @default.
• W2058769962 hasConcept C183713625 @default.
• W2058769962 hasConcept C185592680 @default.
• W2058769962 hasConcept C190283241 @default.
• W2058769962 hasConcept C203092338 @default.
• W2058769962 hasConcept C2776694085 @default.
• W2058769962 hasConcept C2776820818 @default.
• W2058769962 hasConcept C2777472916 @default.
• W2058769962 hasConcept C2777802072 @default.
• W2058769962 hasConcept C2778822529 @default.
• W2058769962 hasConcept C29730261 @default.
• W2058769962 hasConcept C31760486 @default.
• W2058769962 hasConcept C535046627 @default.
• W2058769962 hasConcept C55493867 @default.
• W2058769962 hasConcept C71924100 @default.
• W2058769962 hasConcept C75217442 @default.
• W2058769962 hasConcept C90924648 @default.
• W2058769962 hasConcept C98274493 @default.
• W2058769962 hasConceptScore W2058769962C126322002 @default.
• W2058769962 hasConceptScore W2058769962C126894567 @default.
• W2058769962 hasConceptScore W2058769962C141071460 @default.
• W2058769962 hasConceptScore W2058769962C143998085 @default.
• W2058769962 hasConceptScore W2058769962C183713625 @default.
• W2058769962 hasConceptScore W2058769962C185592680 @default.

• next